Anti-Malarial Drugs Market Size to Exceed USD 1,471.4 Mn by 2032

The Anti-Malarial Drugs Market, estimated at USD 1,081.2 Mn in 2025, is expected to exhibit a CAGR of 4.5% and reach USD 1,471.4 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

The key market players are focusing on various growth strategies partnership and others for research and development activities, which in turn is expected to fuel the growth of global anti-malarial drugs market over the forecast period. For instance, in November 2022, Iktos, an innovative company specializing in the development of artificial intelligence (AI) solutions applied to chemical research, announced a collaboration with Medicines for Malaria Venture (MMV), a product development partnership in the field of antimalarial drug research and development. Under this collaboration agreement, Iktos will apply its new ‘DockAI’ technology to expedite the discovery of novel antimalarial drug candidates.

Global Anti-malarial Drugs Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), that first appeared in Wuhan (province of Hubei, China), in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

The COVID-19 affected the economy in three main ways:  by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding transportation of drugs from one place to another.

The COVID-19 had a positive impact on the global anti-malarial drugs market, as key players operating in the market are focused on development of anti-malarial drugs for the treatment of COVID-19 pandemic. Anti-malarial drugs such as chloroquine, hydroxychloroquine, ferroquine, and others, showed in vitro antiviral effective activity against SARS-CoV-2, which increases the focus of key players on the research and development of anti-malarial drugs for the treatment of anti-malarial as well as for COVID-19. For instance, in September 2020, according to an article published by the Elsevier, in the journal of Travel Medicine and Infectious Disease, an article described how the anti-malarial drugs inhibits the replication of SARS-CoV-2 by an in-vitro evaluation.

Global Anti-malarial Drugs Market: Key Developments

In November 2022, Novartis AG, a global pharmaceutical company, and MMV, a product development partnership in the field of antimalarial drug research and development, announced the decision to progress ganaplacide/lumefantrine- solid dispersion formulation (SDF) into Phase III development for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum. Ganaplacide is a novel agent with a new mechanism of action, which is combined with a new formulation of lumefantrine optimized for once-daily dosing. This combination has the potential not only to clear malaria infection, including artemisinin-resistant strains, but also to block the transmission of the malaria parasite. The medicine is being developed with scientific and financial support from MMV and their partners.

On April 23, 2023, Ocean Biomedical, Inc., a biopharma company, working to accelerate the development and commercialization of scientifically compelling assets from research universities and medical centers, announced that its Scientific Co-founder and a member of its board of directors, received a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for his U.S. patent application covering a therapeutic and prophylactic monoclonal antibody that kills falciparum malaria parasites.

In August 2022, the British Heart Foundation planned to fund the University of Surrey to study on the implications of anti-malaria medicines on cardiac rhythm. It is to understand how drugs used to treat malaria impact the human heart.

In March 2022, tafenoquine a new drug that can cure a certain type of malaria was approved in Australia by Medicines for Malaria Venture (MMV), which helped develop the drug with GlaxoSmithKline (GSK), a multinational pharmaceutical and biotechnology company. The drug is used in combination with the traditional malaria drug chloroquine for kids.

Browse 34 Market Data Tables and 28 Figures spread through 180 Pages and in-depth TOC on “Global Anti-malarial Drugs Market, by Drug Class (Aminoquinolines, Quinoline-methanol (4-quinolinemethanols), Cinchona Alkaloids, Biguanides, Sulfonamides and Sulfones, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)”

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/anti-malarial-drugs-market-3726

Key Takeaways of the Global Anti-malarial Drugs Market:

• Global anti-malarial drugs market is expected to exhibit a CAGR of 4.5% during the forecast period, owing to research and development by the key market players for malarial treatment. For instance, in April 2021, Walter and Eliza Hall Institute for Medical Research in Melbourne, Australia, a medical research institute and Janssen Pharmaceutical, a pharmaceutical R&D (Research and Development) data science team at Johnson & Johnson with assistance from Johnson & Johnson Innovation, announced the collaboration which aimed at identifying and developing potential new antimalarial drug candidate drugs. The collaboration has already discovered promising compounds with antimalarial activity from among 80,000 drug-like molecules in the Janssen Jumpstarter Compound Library, a collection of drug-like compounds designed to fast-track discovery of new medicines.
• Among Drug Class, aminoquinolines segment is expected to be the dominant region in the global anti-malarial drugs market, owing to increasing its use for the treatment of antiviral, antimalarial as well as COVID-19, the key players are focusing on growth strategies such as research and development and others such as acquisitions, partnerships which is expected to propel the market growth. For instance, in March 2022, according to the University of Pittsburgh Medical Center (UPMC), a new study suggests that the malaria drug hydroxychloroquine inhibits pathways that drive resistance to the chemotherapy agent cisplatin in head and neck cancers and restores tumor-killing effects of cisplatin in animal models.
• Among Region, Asia Pacific is expected to be the dominant region in the global anti-malarial drugs market, owing to increasing risk of malaria in the region. For instance, in July 2020, online library of the Organization for Economic Cooperation and Development (OECD), an estimated about 2.31 billion people are at high risk in Asia-Pacific by malaria,
• Major players operating in the global anti-malarial drugs market include Ipca Laboratories Ltd., Zydus Group, Merck KGaA, Pfizer Inc., GSK plc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Alvizia Health Care, Bayer AG, and F. Hoffmann-La Roche Ltd.